Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: Relations of change in bone mineral density, bone markers, and calcium homeostasis

Johannes W.G. Jacobs*, Ron N.J. De Nijs, Willem F. Lems, Piet P.M.M. Geusens, Roland F.J. Laan, Anne Margriet Huisman, Ale Algra, Erik Buskens, Lorenz C. Hofbauer, Ans C.M. Oostveen, George A.W. Bruyn, Ben A.C. Dijkmans, Johannes W.J. Bijlsma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)

Abstract

Objective. To explore the relation of changes in measures of bone turnover and changes in bone mineral density (BMD) of the lumbar spine and total hip over 18 months in a double-blinded, randomized trial, comparing the effect of alfacalcidol (101 patients) versus alendronate (100 patients) on BMD in patients who recently started treatment with glucocorticoids for various rheumatic diseases. Methods. Associations between changes in serum procollagen type I C-propeptide (PICP), fasting urine N-terminal telopeptide of type I collagen (NTx), serum calcium, parathyroid hormone (PTH), osteocalcin, and change from baseline in BMD over 18 months were explored with regression and correlation analyses. Results. In both treatment groups, there was a statistically significant decrease in NTx. In the alfacalcidol group there was also a significant increase in PICP and osteocalcin, in contrast to the alendronate group, but BMD in the alfacalcidol decreased versus an increase in the alendronate group (p < 0.001). In neither treatment group were changes in biochemical measures correlated with the change in BMD, with the exception of a negative correlation in the alendronate group between changes in total hip BMD and NTx. Use of alendronate resulted in an increased PTH in 27 patients, but the increase in BMD of these patients was not statistically significantly different compared to patients taking alendronate with normal PTH levels. Conclusion. Changes in BMD were not associated with changes in bone measures, with the exception of NTx in the alendronate group. For the patient taking glucocorticoids in clinical practice, the value of serial assessment of bone markers is low; changes in markers are no substitute for changes in BMD.

Original languageEnglish
Pages (from-to)1051-1057
Number of pages7
JournalJournal of Rheumatology
Volume34
Issue number5
Publication statusPublished - 1 May 2007

Keywords

  • Alendronate
  • Alfacalcidol
  • Bone markers
  • Bone mineral density
  • Glucocorticoids
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: Relations of change in bone mineral density, bone markers, and calcium homeostasis'. Together they form a unique fingerprint.

Cite this